Maria Tsoli

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.

Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.

The important role of routine cytopathology in pediatric precision oncology.

Parents' experiences of postmortem tumor donation for high-grade gliomas: benefits and suggested improvements.

In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.

Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.

From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer.

loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma.

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.

Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.

From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients.

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.

Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.

Development of Orthotopic Patient-Derived Xenograft Models of Pediatric Intracranial Tumors.

Germline analysis of an international cohort of pediatric diffuse midline glioma patients.